Archemix Corporation

1 Hampshire Street,
5th Floor,
Cambridge,
MA 02139
United States of America
Tel: 617-621-7700
Fax: 617-621-9300

Archemix is a biopharmaceutical company committed to the discovery and development of aptamer-based therapeutics

Archemix and Dicerna to Collaborate on Conjugated Aptamer-Dicer Substrate RNAi Therapeutics
Companies combine proprietary aptamer and gene silencing technologies to maximize therapeutic potential of oligonucleotide drug candidates.

Archemix Earns Milestone Payment from Initiation of Phase 1 Clinical Trial by Nuvelo
The milestone payment has been triggered by Nuvelo’s enrollment of the first volunteer in a Phase 1 study of NU172, a thrombin-inhibiting aptamer.

Archemix and Isis Form Strategic Alliance for Aptamer Drug Discovery and Development
The agreement includes a broad intellectual property license agreement and research collaboration covering proprietary chemistries and oligonucleotide-based therapeutics.